Abstract
Aims
The aim of the study was to investigate whether differences in paracetamol pharmacokinetics (PK) between spinal muscular atrophy (SMA) patients and healthy controls (HC) could be attributed to specific clinical covariates.
Methods
Nonlinear mixed-effects modelling (NONMEM 7.4) was used to develop a population PK model, explore covariates for paracetamol and its metabolites and perform simulations.
Results
With body weight as allometric scaling in the model, SMA disease resulted in a 58% (95% confidence interval [CI]: 20%–130%) increase in the volume of distribution for paracetamol and its metabolites compared to healthy controls. Decreased plasma myoglobin and plasma bilirubin concentrations, seen in SMA patients, resulted in a higher paracetamol leftover clearance (SMA, median: 13.30 L/h/70 kg, 95% CI: 9.14–18.29%; HC, median: 4.05 L/h/70 kg, 95% CI: 3.38–8.83%) and a shift from slower sulfate formation clearance (SMA, median: 8.78 L/h/70 kg, 95% CI: 7.22–9.61%; HC, median: 9.30 L/h/70 kg, 95% CI: 8.42–10.15%) and faster oxidative metabolites elimination clearance (SMA, median: 3.74 L/h/70 kg, 95% CI: 3.31–4.72%; HC, median: 3.25 L/h/70 kg, 95% CI: 2.87–3.92%). Simulations revealed that in SMA patients, higher bodyweight was associated with increased exposure to paracetamol and its metabolites.
Conclusions
The differences in PK between SMA patients and healthy controls could be explained by body weight and the disease itself. SMA patients should be dosed cautiously, ensuring doses do not exceed the recommended body weight adjusted limit.
The aim of the study was to investigate whether differences in paracetamol pharmacokinetics (PK) between spinal muscular atrophy (SMA) patients and healthy controls (HC) could be attributed to specific clinical covariates.
Methods
Nonlinear mixed-effects modelling (NONMEM 7.4) was used to develop a population PK model, explore covariates for paracetamol and its metabolites and perform simulations.
Results
With body weight as allometric scaling in the model, SMA disease resulted in a 58% (95% confidence interval [CI]: 20%–130%) increase in the volume of distribution for paracetamol and its metabolites compared to healthy controls. Decreased plasma myoglobin and plasma bilirubin concentrations, seen in SMA patients, resulted in a higher paracetamol leftover clearance (SMA, median: 13.30 L/h/70 kg, 95% CI: 9.14–18.29%; HC, median: 4.05 L/h/70 kg, 95% CI: 3.38–8.83%) and a shift from slower sulfate formation clearance (SMA, median: 8.78 L/h/70 kg, 95% CI: 7.22–9.61%; HC, median: 9.30 L/h/70 kg, 95% CI: 8.42–10.15%) and faster oxidative metabolites elimination clearance (SMA, median: 3.74 L/h/70 kg, 95% CI: 3.31–4.72%; HC, median: 3.25 L/h/70 kg, 95% CI: 2.87–3.92%). Simulations revealed that in SMA patients, higher bodyweight was associated with increased exposure to paracetamol and its metabolites.
Conclusions
The differences in PK between SMA patients and healthy controls could be explained by body weight and the disease itself. SMA patients should be dosed cautiously, ensuring doses do not exceed the recommended body weight adjusted limit.
| Original language | English |
|---|---|
| Journal | British Journal of Clinical Pharmacology |
| ISSN | 0264-3774 |
| DOIs | |
| Publication status | E-pub ahead of print - 2025 |